Paris, France – December 13, 2018 – Pixium Vision (FR0011950641 – PIX), a bioelectronics company developing innovative bionic vision systems to enable patients who have lost their sight to lead more independent lives, announces today that it has been awarded the Prix Galien 2018 in the “Research Project” category for its PRIMA device for the treatment of dry Age-related Macular Degeneration (AMD).
The Galien Foundation attributes this award to Pixium Vision in recognition of the innovative technology of its PRIMA wireless sub-retinal implant, a “brain-machine” interface applied to the eye to create bionic vision in the treatment of persons with dry AMD. The PRIMA device was chosen from a selection of premier projects supported by prestigious academic institutions.
Khalid Ishaque, CEO of Pixium Vision, comments: “It is with pleasure that our entire team of scientific, engineering and medical researchers receives this prestigious award. The Galien Award attests to the very innovative nature of our PRIMA technology owing to elicit visual perception for patients with dry AMD. We are extremely honoured that the Galien Foundation recognizes PRIMA’s major technological and medical advances, which offer new possibilities in the field of bionic vision for the treatment of retinal diseases. We would like to thank the first patients in our clinical trial for their contribution in this breakthrough human endeavour, which will enable us to continue pursuit of our mission.”
“We are proud to accompany Pixium Vision in developing its breakthrough technology, today awarded the Galien Prize. We congratulate the whole team for this highly valuable scientific recognition.” stated Chahra Louafi et Maïlys Ferrère, Investment Directors at Bpifrance.
Created as a “pharmaceutical research award” in France in 1970, the prestigious Prix Galien is recognised by the French authorities for its public interest and has an international reputation. Each year, the Prix Galien recognises the best healthcare innovations in five categories: pharmaceutical products, medical systems, e-health, patient care and research. The Prix Galien is awarded by a jury comprised of 50 international experts in healthcare. Their independence, authority and reputation confirm the excellence and credibility of the Galien Prize.
Didier Laurens, CFO
+33 1 76 21 47 68
Annie-Florence Loyer – email@example.com
+33 1 44 71 00 12 / +33 6 88 20 35 59
Léa Jacquin – firstname.lastname@example.org
+33 1 44 71 94 94
US Investor Relations
+1 646 277 12 66
PRIMA is a new generation miniaturized and totally wireless sub-retinal implant. The 2×2 millimeters wide and 30 microns thick photovoltaic chip contains 378 electrodes. Implanted under the retina via a minimally invasive surgical procedure, it acts like an array of tiny solar panel powered by pulsed near infrared light projected from a miniature projector integrated into augmented reality glasses, along with a mini-camera. PRIMA is designed to restore sight in patients blinded by retinal dystrophies – a very significant unmet medical need. The target population includes patients with atrophic dry Age-related Macular Degeneration (dry AMD), and also Retinitis Pigmentosa (RP). In addition to a clinical trial with five atrophic dry-AMD patients in France, PRIMA is approved for a similar five-patients study in USA.
ABOUT AGE-RELATED MACULAR DEGENERATION (AMD)
Age-related macular degeneration is the leading cause of severe vision loss and legal blindness in people over the age of 65 in North America and Europe. The global impact is significant with current projected estimates1 for people living with AMD of around 196 million people worldwide and expected rapid growth due to ageing population. Around 1000 new patients are diagnosed everyday just in Europe and USA. There are two forms of advanced AMD: the wet form, where treatment like anti-VEGF injections slows down the disease progression, and the dry form that is most frequent, where there is currently no curative treatment available. More than 5 million patients are afflicted with advanced dry AMD, also referred to as Geographic Atrophy. Patients suffering from this retinal dystrophy gradually lose their central vision (responsible for high visual acuity, e.g. for reading and face recognition) due to loss of photoreceptors.
ABOUT PIXIUM VISION
Pixium Vision’s mission is to create a world of bionic vision for those who have lost their sight, enabling them to regain partial visual perception and greater autonomy. Pixium Vision’s bionic vision systems are associated with a surgical intervention and a rehabilitation period. Pixium Vision is in clinical stage with PRIMA, its sub-retinal miniature photovoltaic wireless implant system, designed for patients who have lost their sight due to outer retinal degeneration, initially for atrophic dry age-related macular degeneration (dry AMD). Pixium Vision collaborates closely with academic and research partners spanning across the prestigious Vision research institutions including Stanford University in California, Institut de la Vision in Paris, Moorfields Eye Hospital in London, Institute of Ocular Microsurgery (IMO) in Barcelona, and UPMC in Pittsburgh, PA. The company is EN ISO 13485 certified and qualifies as “Entreprise Innovante” by Bpifrance.
For more information, please visit: www.pixium-vision.com;
And follow us on: @PixiumVision; www.facebook.com/pixiumvision
This press release may expressly or implicitly contain forward-looking statements relating to Pixium Vision and its activity. Such statements are related to known or unknown risks, uncertainties and other factors that could lead actual results, financial conditions, performance or achievements to differ materially from Vision Pixium results, financial conditions, performance or achievements expressed or implied by such forward looking statements.
Pixium Vision provides this press release as of the aforementioned date and does not commit to update forward looking statements contained herein, whether as a result of new information, future events or otherwise.
For a description of risks and uncertainties which could lead to discrepancies between actual results, financial condition, performance or achievements and those contained in the forward-looking statements, please refer to Chapter 4 “Risk Factors” of the company’s Registration Document filed with the AMF under number R16-033 on April 28, 2016 which can be found on the websites of the AMF – AMF (www.amf-france.org) and of Pixium Vision (www.pixium-vision.com).
IRIS® is a trademark of Pixium-Vision SA